Skip to main content

Table 2 IBD PRTI scores at Week 8 (observed population)

From: Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes

IBD PRTI component score, mean (SE)

Placebo (n = 43)

Tofacitinib BID

0.5 mg (n = 29)

3 mg (n = 33)

10 mg (n = 31)

15 mg (n = 47)

Patient global satisfactiona

3.2 (0.2)

3.2 (0.3)

3.5 (0.2)

3.7 (0.2)

4.3 (0.1)

Patient global preferenceb

2.8 (0.2)

2.6 (0.3)

2.4 (0.2)

2.2 (0.2)

1.5 (0.1)

Patient willingness to use drug againc

2.3 (0.2)

2.8 (0.3)

2.4 (0.2)

2.2 (0.2)

1.6 (0.1)

  1. aExtremely dissatisfied with study drug = 1, Dissatisfied with study drug = 2, Neither satisfied nor dissatisfied with study drug = 3, Satisfied with study drug = 4, Extremely satisfied with study drug = 5.
  2. bDefinitely prefer study drug over prior treatment = 1, Slightly prefer study drug = 2, No preference = 3, Slightly prefer prior treatment = 4, Definitely prefer prior treatment = 5.
  3. cWould definitely use study drug again = 1, Might use study drug again = 2, Not sure = 3, Might not use study drug again = 4, Would definitely not use study drug again = 5.
  4. BID, twice daily; PRTI, IBD Patient-Reported Treatment Impact (Version 2) survey; SE, standard error.
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us